Search results
Results from the WOW.Com Content Network
Casgevy costs $2.2 million in the U.S. While CRISPR Therapeutics and Vertex estimate a target market of 35,000 patients in the U.S. and Europe, it won't matter if the medicine is inaccessible to ...
The CRISPR Journal is a peer-reviewed scientific journal published every three months by Mary Ann Liebert. It covers research on all aspects of CRISPR research, including its uses in synthetic biology and genome editing .
The use of the CRISPR-Cas9-gRNA complex for genome editing [10] was the AAAS's choice for Breakthrough of the Year in 2015. [11] Many bioethical concerns have been raised about the prospect of using CRISPR for germline editing, especially in human embryos . [ 12 ]
On 26 November 2018, The CRISPR Journal published ahead of print an article by He, Ryan Ferrell, Chen Yuanlin, Qin Jinzhou, and Chen Yangran in which the authors justified the ethical use of CRISPR gene editing in humans. [74] As the news of CRISPR babies broke out, the editors reexamined the paper and retracted it on 28 December, announcing:
Over recent years, many groups have successfully used genome-wide CRISPR/Cas9 as a screening strategy for HDFs in viral infections. [ 59 ] One example is provided by Marceau et al. (2017), [ 60 ] who aimed to dissect the host factors associated with dengue and hepatitis C (HCV) infection (two viruses in family Flaviviridae ).
Image source: Getty Images. 1. Pfizer. Pfizer (NYSE: PFE) stood out a few years ago thanks to its coronavirus products and a portfolio of blockbuster drugs.Today, demand for coronavirus vaccines ...
CRISPR Made Simple — an educational guide to CRISPR for younger students and teachers. [ 70 ] CasPEDIA — a wiki-style database of the known CRISPR-associated (Cas) proteins, their activity and use cases, launched in 2023 by a group of researchers at the IGI.
Victoria Gray was the first patient ever to be treated with the gene-editing tool CRISPR for sickle-cell disease. [1]This marked the initial indication that a cure is attainable for individuals born with sickle-cell disease and another severe blood disorder, beta-thalassemia.